Division of Molecular Modification and Cancer Biology, National Cancer Center Research Institute, Tokyo, Japan
Cancer Translational Research Team, RIKEN Center for Advanced Intelligence Project, Tokyo, Japan.
In Vivo. 2019 Sep-Oct;33(5):1659-1665. doi: 10.21873/invivo.11652.
BACKGROUND/AIM: The aim of this study was to compare the clinical outcomes of patients treated by local radiotherapy or chemotherapy for oligo-recurrent cervical cancer with prior pelvic irradiation.
Forty-one patients who had received pelvic irradiation for cervical cancer developed oligo-recurrent (≤5 lesions) relapses and underwent local radiotherapy (n=22) or systemic chemotherapy (n=19). Overall survival (OS), local recurrence-free survival (LRFS) and distant-free survival (DFS) were estimated, and risk factors were identified.
The median follow-up was 24.1 months. The group of local radiotherapy showed a significantly superior LRFS, but inferior DFS. There was no significant difference in OS. Multivariate analysis revealed that FIGO stage at initial diagnosis was associated with OS. For patients with early FIGO stages (IB-IIB), local radiotherapy provided a tendency toward longer OS than chemotherapy.
Out-field oligo-recurrence in patients with initial early FIGO stages may be an indication of salvage radiotherapy.
背景/目的：本研究旨在比较既往盆腔放疗后寡复发宫颈癌患者接受局部放疗或化疗的临床结局。
41 例宫颈癌患者接受盆腔放疗后出现寡复发（≤5 个病灶）复发，并接受局部放疗（n=22）或全身化疗（n=19）。估计总生存期（OS）、局部无复发生存期（LRFS）和无远处转移生存期（DFS），并识别危险因素。
中位随访时间为 24.1 个月。局部放疗组的 LRFS 明显更好，但 DFS 较差。OS 无显著差异。多因素分析显示，初始诊断时的 FIGO 分期与 OS 相关。对于早期 FIGO 分期（IB-IIB）的患者，局部放疗提供了比化疗更长的 OS 的趋势。
初诊时为早期 FIGO 分期的患者的野外寡复发可能是挽救性放疗的指征。
